Disease Prognosis and Progression in Transthyretin Amyloidosis: JACC: CardioOncology State-of-the-Art Review.

Transthyretin amyloidosis (ATTR) is a rapidly evolving disease with a rising prevalence and improving prognosis. With an increasing number of patients diagnosed across a broad spectrum of disease stages, disease prognostication is pivotal to guiding therapeutic decisions. Similarly, with varying phenotypes identified and an expanding range of disease-modifying treatments available, the timely identification of cardiac and extracardiac disease progression remains essential. In this review, the authors highlight the current state of knowledge for disease prognosis and progression in ATTR. They focus on clinical, biomarker, functional, and imaging markers of cardiac disease progression. The authors also highlight the need for further investigation into neurologic and other noncardiac indicators of disease progression. Finally, they discuss current approaches and future directions for disease monitoring in ATTR.